Van Berkom & Associates Inc. Has $91.15 Million Stock Position in Privia Health Group, Inc. $PRVA

Key Points

• Van Berkom & Associates increased its stake in Privia Health to 3,844,256 shares (about $91.15 million), making PRVA its 10th-largest holding and roughly 2.6% of the fund's portfolio.
• Insiders sold shares recently—CEO Parth Mehrotra sold 26,509 shares at ~$22.11 and EVP Edward Fargis sold 4,949 shares—with insiders offloading 247,757 shares (~$5.64M) over the past 90 days, while insiders still own 5.70% of the stock.
• Analysts carry a consensus rating of "Moderate Buy" with an average price target of $31.31, and Privia recently beat estimates (Q reported EPS $0.25 vs $0.04 est; revenue $541.17M, +17.4% YoY).

Van Berkom & Associates Inc. grew its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,844,256 shares of the company's stock after purchasing an additional 69,691 shares during the period. Privia Health Group comprises approximately 2.6% of Van Berkom & Associates Inc.'s investment portfolio, making the stock its 10th biggest holding. Van Berkom & Associates Inc. owned approximately 3.13% of Privia Health Group worth $91,147,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board grew its position in shares of Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company's stock worth $85,000 after buying an additional 1,200 shares during the period. GAMMA Investing LLC lifted its stake in Privia Health Group by 198.5% in the fourth quarter. GAMMA Investing LLC now owns 4,314 shares of the company's stock worth $102,000 after acquiring an additional 2,869 shares during the period. Raymond James Financial Inc. bought a new position in Privia Health Group in the second quarter worth $113,000. Covestor Ltd increased its holdings in Privia Health Group by 39.8% in the 3rd quarter. Covestor Ltd now owns 5,824 shares of the company's stock worth $145,000 after buying an additional 1,657 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Privia Health Group during the 1st quarter valued at about $154,000. Institutional investors own 94.48% of the company's stock.

Insiders Place Their Bets

In related news, CEO Parth Mehrotra sold 26,509 shares of Privia Health Group stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99. Following the completion of the sale, the chief executive officer owned 555,443 shares of the company's stock, valued at $12,280,844.73. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Edward C. Fargis sold 4,949 shares of the company's stock in a transaction on Monday, March 9th. The shares were sold at an average price of $22.84, for a total value of $113,035.16. Following the completion of the sale, the executive vice president owned 83,711 shares of the company's stock, valued at approximately $1,911,959.24. The trade was a 5.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 247,757 shares of company stock valued at $5,636,639. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on PRVA shares. Evercore set a $26.00 price objective on Privia Health Group in a report on Wednesday, April 8th. Barclays lifted their price objective on Privia Health Group from $23.00 to $25.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 25th. Piper Sandler restated an "overweight" rating and set a $36.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Wolfe Research set a $31.00 target price on Privia Health Group in a research report on Tuesday, January 6th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Privia Health Group in a report on Friday, March 27th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $31.31.

Privia Health Group Stock Performance

NASDAQ PRVA opened at $24.24 on Tuesday. The company has a 50-day simple moving average of $22.59 and a 200 day simple moving average of $23.37. Privia Health Group, Inc. has a 52-week low of $18.77 and a 52-week high of $26.51. The company has a market capitalization of $3.05 billion, a PE ratio of 142.59, a price-to-earnings-growth ratio of 1.55 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.04 by $0.21. The company had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm's revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.21 earnings per share. As a group, analysts forecast that Privia Health Group, Inc. will post 0.37 EPS for the current fiscal year.

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.